Product Sales
Full Year 2020 Product Sales
The following table provides the top 20 Innovative Medicines Division product net sales in 2020 as well as the change compared to 2019:
| Brands | Net Sales (USD m) | % change (USD) | Business Franchise |
|---|---|---|---|
| Cosentyx | 3,995 | 13% | Immunology, Hepatology and Dermatology |
| Gilenya | 3,003 | -7% | Neuroscience |
| Entresto | 2,497 | 45% | Cardiovascular, Renal and Metabolism |
| Tasigna | 1,958 | 4% | Oncology |
| Lucentis | 1,933 | -7% | Ophthalmology |
| Promacta/Revolade | 1,738 | 23% | Oncology |
| Tafinlar + Mekinist | 1,542 | 15% | Oncology |
| Sandostatin | 1,439 | -9% | Oncology |
| Jakavi | 1,339 | 20% | Oncology |
| Xolair1 | 1,251 | 7% | Respiratory |
| Galvus Group | 1,199 | -8% | Established Medicines |
| Gleevec/Glivec | 1,188 | -6% | Oncology |
| Afinitor/Votubia | 1,083 | -30% | Oncology |
| Diovan Group | 1,003 | -6% | Established Medicines |
| Exforge Group | 980 | -4% | Established Medicines |
| Zolgensma | 920 | 155% | Neuroscience |
| Ilaris | 873 | 30% | Immunology, Hepatology and Dermatology |
| Kisqali | 687 | 43% | Oncology |
| Exjade/Jadenu | 653 | -33% | Oncology |
| Votrient | 635 | -16% | Oncology |
- Net sales reflect Xolair sales for all indications.